Swarm accelerometer data processing from raw accelerations to thermospheric neutral densities

The Swarm satellites were launched on November 22, 2013, and carry accelerometers and GPS receivers as part of their scientific payload. The GPS receivers do not only provide the position and time for the magnetic field measurements, but are also used for determining non-gravitational forces like drag and radiation pressure acting on the spacecraft. The accelerometers measure these forces directly, at much finer resolution than the GPS receivers, from which thermospheric neutral densities can be derived. Unfortunately, the acceleration measurements suffer from a variety of disturbances, the most prominent being slow temperature-induced bias variations and sudden bias changes. In this paper, we describe the new, improved four-stage processing that is applied for transforming the disturbed acceleration measurements into scientifically valuable thermospheric neutral densities. In the first stage, the sudden bias changes in the acceleration measurements are manually removed using a dedicated software tool. The second stage is the calibration of the accelerometer measurements against the non-gravitational accelerations derived from the GPS receiver, which includes the correction for the slow temperature-induced bias variations. The identification of validity periods for calibration and correction parameters is part of the second stage. In the third stage, the calibrated and corrected accelerations are merged with the non-gravitational accelerations derived from the observations of the GPS receiver by a weighted average in the spectral domain, where the weights depend on the frequency. The fourth stage consists of transforming the corrected and calibrated accelerations into thermospheric neutral densities. We present the first results of the processing of Swarm C acceleration measurements from June 2014 to May 2015. We started with Swarm C because its acceleration measurements contain much less disturbances than those of Swarm A and have a higher signal-to-noise ratio than those of Swarm B. The latter is caused by the higher altitude of Swarm B as well as larger noise in the acceleration measurements of Swarm B. We show the results of each processing stage, highlight the difficulties encountered, and comment on the quality of the thermospheric neutral density data set.Astrodynamics & Space Mission

A novel preclinical model for rheumatoid arthritis research

Based on increasing knowledge on the pathogenesis of rheumatoid arthritis (RA), more and more potential therapeutics have been developed. To evaluate their therapeutic efficacy, safety and toxicity, appropriate animal models are required. Although rodent models of RA have been extensively used for preclinical evaluation, the differences between rodents and humans limit their usability for some species-specific therapeutics. Therefore, autoimmune arthritis developed in a non-human primate with essential hallmarks of RA will be an alternative model for preclinical studies

Role of endogenous and exogenous female sex hormones in arthritis and osteoporosis development in B10.Q-ncf1*/* mice with collagen-induced chronic arthritis

<p>Abstract</p> <p>Background</p> <p>Collagen-induced arthritis (CIA) is an often-used murine model for human rheumatoid arthritis (RA). Earlier studies have shown potent anti-arthritic effects with the female sex hormone estradiol and the selective estrogen receptor modulator (SERM) raloxifene in CIA in DBA/1-mice. B10.Q-ncf1^*/*mice are B10.Q mice with a mutated Ncf1 gene. In B10.Q-ncf1^*/*mice, CIA develops as a chronic relapsing disease, which more accurately mimics human RA. We investigated the role of endogenous and exogenous sex steroids and raloxifene in the course of this model of chronic arthritis. We also examined whether treatment would prevent the development of inflammation-triggered generalized osteoporosis.</p> <p>Methods</p> <p>Female B10.Q-ncf1^*/*mice were sham-operated or ovariectomized, and CIA was induced. 22 days later, when 30% of the mice had developed arthritis, treatment with raloxifene, estradiol or vehicle was started, and the clinical disease was evaluated continuously. Treatment was continued until day 56 after immunization. At termination of the experiment (day 73), bone mineral density (BMD) was analyzed, paws were collected for histological examination, and sera were analyzed for markers of cartilage turnover and pro-inflammatory cytokines.</p> <p>Results</p> <p>Raloxifene and estradiol treatment, as well as endogenous estrogen, decreased the frequency of arthritis, prevented joint destruction and countered generalized osteoporosis. These effects were associated with lower serum levels of the pro-inflammatory cytokine IL-6.</p> <p>Conclusions</p> <p>This is the first study to show that raloxifene and estradiol can ameliorate established erosive arthritis and inflammation-triggered osteoporosis in this chronic arthritis model. We propose that treatment with raloxifene could be a beneficial addition to the treatment of postmenopausal RA.</p

Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis

The definitive version is available at www3.interscience.wiley.comType II collagen (CII) posttranslationally modified by reactive oxygen species (ROS-CII) that are present in the inflamed joint is an autoantigen in rheumatoid arthritis (RA). The aim of this study was to investigate the potential use of anti-ROS-CII autoantibodies as a biomarker of RA

Transitional Care for Patients with Congenital Colorectal Diseases: An EUPSA Network Office, ERNICA, and eUROGEN Joint Venture

Background: Transition of care (TOC; from childhood into adulthood) of patients with anorectal malformations (ARM) and Hirschsprung disease (HD) ensures continuation of care for these patients. The aim of this international study was to assess the current status of TOC and adult care (AC) programs for patients with ARM and HD. Methods: A survey was developed by members of EUPSA, ERN eUROGEN, and ERNICA, including patient representatives (ePAGs), comprising of four domains: general information, general questions about transition to adulthood, and disease-specific questions regarding TOC and AC programs. Recruitment of centres was done by the ERNs and EUPSA, using mailing lists and social media accounts. Only descriptive statistics were reported. Results: In total, 82 centres from 21 different countries entered the survey. Approximately half of them were ERN network members. Seventy-two centres (87.8%) had a self-reported area of expertise for both ARM and HD. Specific TOC programs were installed in 44% of the centres and AC programs in 31% of these centres. When comparing centres, wide variation was observed in the content of the programs. Conclusion: Despite the awareness of the importance of TOC and AC programs, these programs were installed in less than 50% of the participating centres. Various transition and AC programs were applied, with considerable heterogeneity in implementation, content and responsible caregivers involved. Sharing best practice examples and taking into account local and National Health Care Programs might lead to a better continuation of care in the future. Level of Evidence: III